Niagen Bioscience (NAGE) Corporate presentation summary

Market opportunity and growth drivers

• Addressing a global anti-aging market projected to surpass $120B by 2030, with a 7% CAGR from 2025-2030.

• Gen Z and Millennials drive 41% of wellness spend in a $500B U.S. market growing 4-5% annually.

• Significant opportunities in human and pet nutrition, IV/injectables, cosmetics, and pharmaceuticals.

• Strategic partnerships with blue chip companies and expanding global distribution footprint.

• E-commerce represents over 50% of business, with a 66% CAGR since 2017.

Product innovation and scientific leadership

• Developed Niagen®, a patented NAD+ booster, and Tru Niagen®, the #1 NAD+ healthy aging supplement in the U.S.

• Niagen IV and injectables offer pharma-grade solutions with faster administration and fewer side effects.

• Proprietary NanoCloud™ technology extends NAD+ science into skincare, delivering visible benefits in 2 weeks.

• Over 100 patents and a robust pipeline of next-generation NAD+ precursors.

• Supported by a renowned scientific advisory board, including Nobel laureates and leading researchers.

Clinical validation and research

• Tru Niagen® increases NAD+ by 40-50% after 8 weeks at 300mg/day, with over 40 human clinical studies.

• Clinical studies show positive outcomes in aging, cardiovascular, immune, liver, neurological, and metabolic health.

• Broad pharmaceutical potential with ongoing and completed trials in rare diseases, neurodegeneration, heart, liver, immunity, and more.

• Two independent clinical trials showed NAD+ augmentation improved symptoms in Ataxia Telangiectasia patients.

• Over 300 global research collaborations and $200M+ in third-party research support.